The modulation of TRAIL pathway was reported to mediate resistance to BCL-2 inhibition in solid tumors and CLL,35,39 which was also identified by CRISPR screening in our study. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.